Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Crossover Study to Evaluate Analgesic Efficacy, Safety and Tolerability of Repeated Doses of Topical VMD-3866 in Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN)
Conditions
Interventions
VMD-3866 Gel
Placebo Gel
Locations
1
United Kingdom
Hammersmith Medicines Research Ltd (HMR code 24-503)
London, UK, United Kingdom
Start Date
December 12, 2025
Primary Completion Date
June 30, 2027
Completion Date
December 31, 2027
Last Updated
March 27, 2026
NCT06769061
NCT06162403
NCT07352514
NCT07064798
NCT07164950
NCT06994507
Lead Sponsor
VM Therapeutics LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions